Merck & Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough

 Merck & Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough

Merck & Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough

Shots:

  • The two P-III studies (COUGH-1 &-2) involves assessing of gefapixant (45mg, 15mg, bid) vs PBO in 732 & 1,317 patients with refractory or unexplained chronic cough with 1EP as 24hrs. cough/hr. @12wks. and 24wks. respectively
  • Gefapixant (45mg, bid) arm met its 1EPs i.e, decrease in 24hrs. coughs/hr. @12wks. & 24wks. while gefapixant (15mg, bid) arm did not meet its 1EP, safety & tolerability of gefapixant is consistent with the previous studies
  • Gefapixant (PO) is an investigational, selective P2X3 receptor antagonist, to treat refractory or unexplained chronic cough

Click here ­to­ read full press release/ article | Ref: Merck | Image: Livemint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post